Biogenesis of mRNA-derived telomerase long noncoding RNA
mRNA 衍生端粒酶长非编码 RNA 的生物发生
基本信息
- 批准号:10638429
- 负责人:
- 金额:$ 30.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-16 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:3&apos Untranslated RegionsAlternative SplicingAmino Acid SequenceAnimalsAscomycotaBasidiomycotaBinding ProteinsBiogenesisBiologyCRISPR/Cas technologyCell physiologyChromosomal StabilityCodeComplexDNAEnzymesEukaryotaEvolutionFamilyGenesGeneticGenetic TranscriptionGenome StabilityGoalsIntronsLife Cycle StagesMammalian CellMeasuresMessenger RNAMolecularNucleotidesOutcomePathway interactionsPatternPlantsPlayProcessProtein IsoformsProteinsRNARNA DecayRNA Polymerase IIRNA Polymerase IIIRNA PrecursorsRNA ProcessingRNA SplicingRNA metabolismRNA-Binding ProteinsRegulationResearchRibonucleoproteinsRoleSmall Nuclear RNASmall Nucleolar RNAStructureTechnologyTelomeraseTelomerase RNA ComponentTelomere MaintenanceTranscriptUntranslated RNAUstilagoYeastscancer cellfungusgenetic informationhuman diseaseinnovative technologiesinsightmRNA Precursormodel organismnanoporenovelnucleaseposttranscriptionalprogramsprotein expressionsequencing platformstem cellstool
项目摘要
Project Summary
Most RNA molecules transcribed in mammalian cells do not encode for protein sequences. Among these
noncoding RNAs (ncRNA) is a vast family of long noncoding RNAs (lncRNAs) that are larger than 200 nt.
LncRNAs can modulate cellular protein expression patterns by influencing the transcription of many genes, the
post-transcriptional fate of mRNAs and ncRNAs, and the turnover and localization of proteins. Telomerase
RNA is a unique class of lncRNA that functions as an integral component of the telomerase ribonucleoprotein
complex which maintains genomic stability and cellular immortality in cancer and stem cells. The overarching
goal of this project is to understand the mechanism and regulation of a novel mRNA-derived biogenesis of
telomerase RNA (lncRNA) in Ustilago maydis, a basidiomycete fungus.
Telomerase RNA in Ascomycete yeasts and animals, telomerase RNAs are transcribed by RNA
polymerase II and share biogenesis pathways with small nuclear RNA (snRNA) and box H/ACA small
nucleolar RNA (snoRNA), respectively. In contrast, telomerase RNAs in ciliates and plants are transcribed by
RNA polymerase III. These distinct biogenesis mechanisms employed by these homologous telomerase RNA
molecules from different eukaryotic kingdoms or groups provide unparalleled opportunities for understanding
the fundamental principles underlying the biogenesis and evolution of the vast varieties of noncoding RNA
species in biology.
We have recently identified the first Basidiomycete telomerase RNA from U. maydis, a fungal model
organism. Animal and yeast TRs are transcribed by RNA polymerase II with a protective cap at the 5’-end.
intriguingly, the U. maydis TR lacks a protective 5’ cap and is processed from the 3’-untranslated region of a
protein-coding mRNA precursor. In this research program, we will identify determinants in the TR precursor
that regulate the biogenesis of the mature U. maydis TR from the protein-coding mRNA. We will also study the
function and expression of the protein encoded in the mRNA precursor. Lastly, we will identify telomerase
accessory proteins in U. maydis and determine their roles in regulating the U. maydis TR biogenesis.
Successful outcomes of these specific aims will provide comprehensive and exciting details needed for
understanding the unprecedented mRNA-derived biogenesis mechanism of telomerase lncRNA.
项目摘要
在哺乳动物细胞中转录的大多数RNA分子都不编码蛋白质序列。其中
非编码RNA(NCRNA)是一个大于200 nt的长期非编码RNA(LNCRNA)的庞大家族。
LNCRNA可以通过影响许多基因的转录,即
mRNA和NCRNA的转录后命运,以及蛋白质的周转和定位。端粒酶
RNA是一类独特的lncRNA,它是端粒酶蛋白的组成部分的功能
维持癌症和干细胞中基因组稳定性和细胞永生的复合物。总体
该项目的目标是了解新型mRNA衍生的生物发生的机制和调节
Ustilago Maydis的端粒酶RNA(LNCRNA),一种碱性真菌。
端粒酶RNA在子宫菌酵母和动物中,端粒酶RNA由RNA转录
聚合酶II并用小核RNA(SNRNA)和盒子H/ACA共享生物发生途径
核仁RNA(SNORNA)。相反,纤毛和植物中的端粒酶RNA被转录
RNA聚合酶III。这些同源端粒酶RNA携带的这些独特的生物发生机制
来自不同真核王国或群体的分子为理解提供了无与伦比的机会
非编码RNA的大量生物发生和演变的基本原理
生物学物种。
我们最近确定了来自U. Maydis的第一个基本型端粒酶RNA,一种真菌模型
生物。动物和酵母TR由RNA聚合酶II转录,并在5'末端具有保护帽。
有趣的是,美国Maydis TR缺乏受保护的5'盖,并从A的3英寸未翻译区域进行处理
蛋白质编码mRNA前体。在该研究计划中,我们将确定tr前体中的确定词
从蛋白质编码mRNA中调节成熟的U. Maydis TR的生物发生。我们还将研究
在mRNA前体中编码的蛋白质的功能和表达。最后,我们将确定端粒酶
U. Maydis的辅助蛋白,并确定其在调节美国Maydis TR生物发生中的作用。
这些特定目标的成功结果将为需要提供全面而令人兴奋的细节
了解端粒酶lncRNA的前所未有的mRNA衍生的生物发生机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Julian J-L Chen其他文献
Julian J-L Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Julian J-L Chen', 18)}}的其他基金
Molecular Mechanism of Telomerase Action: Administrative Supplement
端粒酶作用的分子机制:行政补充
- 批准号:
9026451 - 财政年份:2011
- 资助金额:
$ 30.25万 - 项目类别:
Development of a fish model for dyskeratosis congenita and cancer research
开发用于先天性角化不良和癌症研究的鱼类模型
- 批准号:
7512983 - 财政年份:2008
- 资助金额:
$ 30.25万 - 项目类别:
相似海外基金
The mechanism of CELF1 upregulation and its role in the pathogenesis of Myotonic Dystrophy Type 1
CELF1上调机制及其在强直性肌营养不良1型发病机制中的作用
- 批准号:
10752274 - 财政年份:2024
- 资助金额:
$ 30.25万 - 项目类别:
Genetic and pharmacologic elimination of myotonia from myotonic dystrophy type 1
通过遗传和药物消除 1 型强直性肌营养不良引起的肌强直
- 批准号:
10750357 - 财政年份:2023
- 资助金额:
$ 30.25万 - 项目类别:
The role of RNA binding proteins in heart development and congenital heart defects
RNA结合蛋白在心脏发育和先天性心脏缺陷中的作用
- 批准号:
10827567 - 财政年份:2023
- 资助金额:
$ 30.25万 - 项目类别:
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy
预防强直性肌营养不良的新型小分子疗法的设计、合成和功效
- 批准号:
10841887 - 财政年份:2023
- 资助金额:
$ 30.25万 - 项目类别: